NewsRSS2 days ago
This article is a quiz about nerandomilast, a medicine being studied to treat progressive pulmonary fibrosis (PPF), which is a lung disease where lung tissue becomes scarred and stiff over time, making it harder to breathe. The quiz helps patients and caregivers learn more about this potential treatment option. It's a way to test your understanding of how this medicine might help people with this serious lung condition.
WHY IT MATTERSPatients with progressive pulmonary fibrosis have limited treatment options, so learning about emerging therapies like nerandomilast helps them stay informed about potential new ways to slow lung damage.
ResearchBIORXIVApr 5
Researchers studied the genes of people with pulmonary fibrosis (a disease where lung tissue becomes scarred and stiff) to find rare genetic changes that might cause the disease. They found that problems in genes related to how cells maintain their structure may play an important role in developing pulmonary fibrosis. This discovery could help doctors better understand why some people develop this serious lung condition.
WHY IT MATTERSIf you or a family member has pulmonary fibrosis, this research could eventually help explain your genetic risk and lead to new treatments targeting the cellular structures that are damaged in this disease.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for idiopathic pulmonary fibrosis (a lung disease where lung tissue becomes scarred and stiff over time) is currently closed and is not accepting new applications. This program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have idiopathic pulmonary fibrosis and need help paying for medications or treatment, you cannot currently apply to this specific PAN Foundation program, so you'll need to explore other financial assistance options.